Cell based Assays Market

The global cell based assays market in terms of revenue was estimated to be worth $18.9 billion in 2023 and is poised to reach $28.2 billion by 2028, growing at a CAGR of 8.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the growing demand for drug discovery & development and the increasing preference for cell-based assays in drug discovery, the growing government support and funding for cell-based research, and the rising efforts by the FDA to curtail animal-based studies.

Cell Based Assays Market - Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Cell-Based Assays Market

Cell Based Assays Market Dynamics

DRIVER: Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery

The growing demand for drug discovery & development is a major factor driving growth in the cell-based assays market. Cell-based assays play a crucial role in early-stage drug screening by providing valuable insights into the efficacy, safety, and potential side-effects of drug candidates. Researchers can use these assays to assess how drugs interact with cellular targets, enabling the identification of promising compounds for further drug development. This approach offers a cost-effective and time-efficient alternative to animal models, reducing the need for extensive preclinical testing.

RESTRAINT: High cost of instruments and restrictions imposed by product end-user licenses for reagents

The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell-based assays has increased their reliability. However, the initial investment required to acquire the necessary instruments can be substantial, deterring smaller research facilities and resource-limited organizations from adopting these technologies. Moreover, the time and cost involved in each HTS process are directly proportional to the target molecule’s complexity; consequently, the higher the complexity, the greater the cost. In biopharmaceutical companies, the overall cost of production of biopharmaceuticals has increased considerably due to the use of these expensive systems. Academic research laboratories find it difficult to afford such expensive instruments due to budgetary restrictions. Maintenance costs and other indirect expenses result in an overall increase in the total cost of ownership of these instruments. These cost constraints are major challenges to the broader utilization of cell-based assays in various sectors.

OPPORTUNITY: Growing opportunities in emerging economies

The cell-based assays market is poised for growth, with emerging economies offering promising opportunities. These economies, characterized by expanding healthcare infrastructures and increasing investments in research & development, provide a favorable environment for market expansion.

Emerging countries in Asia are expected to offer significant growth opportunities for players operating in the cell-based assays market owing to the low labor and raw material costs, increased risk of pandemics (such as swine flu and COVID-19), growth in the number of research activities, and technological advancements in the end-use sectors for cell-based assays in these countries. Countries like China and India are witnessing significant growth in their pharmaceutical industries. These nations have been actively investing in drug discovery & development, leading to the increased demand for cell-based assays. The expanding populations and rising healthcare expenditures in these economies further contribute to the market.

CHALLENGE: Complexities in assay designs

Complexities in assay designs pose a notable challenge to the growth of the cell-based assays market. Developing robust and reliable assays that accurately reflect in vivo conditions and provide meaningful data is a complex task. The interplay of various cellular factors and processes adds intricacy to assay designs, making it challenging for researchers and developers. The complexity arises from factors such as cell type selection, culture conditions, assay protocols, and endpoint measurements. Designing assays that appropriately mimic the complex cellular environment and accurately assess drug responses requires careful consideration and optimization. Furthermore, incorporating relevant controls and ensuring reproducibility across different laboratories and platforms adds to the complexity.

Global Cell Based Assays Market: Ecosystem

The consumables segment dominated cell based assays industry by product & service

In 2022, the consumables segment emerged as the largest contributor to the cell based assays market. This dominance can be attributed to the consistent usage and frequent replenishment requirements of consumables, which contrasts with instruments that are typically one-time purchases. Several factors are driving the growth of this segment, including the expanding applications of cell-based assays and reagents in drug discovery, the increasing number of promising drug candidates in the pipeline, advancements in automation and detection technologies, and the growing adoption of assay handling systems and cell lines in research activities.

The toxicology studies subsegment dominated the cell based assays industry by drug discovery application

The toxicology studies segment has emerged as a dominant force within the cell based assays market, particularly in the field of drug discovery. With the increasing focus on drug safety and the need to identify potential toxic effects at early stages, cell-based assays have become invaluable tools for toxicology studies. These assays enable researchers to assess the impact of drug candidates on cellular systems and evaluate their potential toxicities. By utilizing cell-based assays, drug developers can identify compounds with unfavorable safety profiles and eliminate them from further development, thereby saving valuable time and resources. The toxicology studies segment offers a comprehensive range of cell-based assays designed to assess various toxicity endpoints, including cytotoxicity, genotoxicity, hepatotoxicity, cardiotoxicity, and neurotoxicity. With the growing demand for safer and more effective drugs, the toxicology studies segment is poised to experience sustained growth, driving advancements in cell-based assay technologies and contributing to the overall progress of drug discovery.

The contract research organizations (CROs) end user segment of cell based assays industry is expected to grow at the highest rate during the forecast period

The contract research organizations (CROs) segment is anticipated to witness the highest growth rate in the cell based assays market during the forecast period. CROs play a vital role in drug discovery and development processes by providing specialized services to pharmaceutical and biotechnology companies. The outsourcing of research activities to CROs offers several advantages, including cost savings, access to expertise, and accelerated timelines. Cell-based assays are an integral part of preclinical and early-stage drug development, and CROs have the necessary infrastructure, resources, and expertise to conduct these assays efficiently. The increasing preference for outsourcing research activities, coupled with the growing complexity of cell-based assays, drives the demand for CRO services in this market. The ability of CROs to offer tailored solutions, flexibility, and comprehensive project management further contributes to their projected high growth rate in the cell-based assays market.

To know about the assumptions considered for the study, download the pdf brochure

Asia Pacific region of the cell based assays industry estimated to register the highest CAGR during the forecast period.

The Asia Pacific region is expected to at the highest CAGR during the forecast period. The cell based assays market in the region is likely to be driven by government initiatives to increase funding in biopharmaceuticals, growing R&D spending, public-private partnerships for life science research, and increasing drug discovery and development studies. Additionally, the rising geriatric population, growth of the healthcare industry, and the availability of basic infrastructure for R&D will support market growth.

Key players in the cell based assays market include Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Becton, Dickinson and Company (US), Lonza (Switzerland), PerkinElmer (US), Charles River Laboratories (US), Eurofins Scientific (France), Enzo Biochem (US), Carna Biosciences (Japan), Cell Biolabs (US), Promega Corporation (US), Cell Signaling Technology (US), BioAgilytix Labs (US), Reaction Biology Corporation (US), AAT Bioquest (US), Pestka Biomedical Laboratories (US), InvivoGen (US), CA3 Biosciences (US), BPS Bioscience (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), and JRS Pharma (Germany).

Scope of the Cell Based Assays Industry

This report categorizes the cell-based assays market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Consumables
• Reagents
• Assay Kits
• Reporter Gene Assays
• Second Messenger Assays
• Cell Growth Assays, Cell Death Assays
• Other Assays
• Cell Lines
• Immortalized Cell Lines
• Primary Cell Lines
• Stem Cell Lines
• Microplates
• Probes & Labels
• Other Consumables
• Instruments & Software
• Services

By Application

• Drug Discovery
• Pharmacodynamic Studies
• Pharmacokinetic Studies
• Toxicity Studies
• Basic Research
• Other Applications

By End user

• Pharmaceutical & Biopharmaceutical Companies
• Contract Research Organizations (Cros)
• Academic & Research Institutes

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
  • Brazil
  • RoLATAM
• Middle East and Africa (MEA)
  • Middle East
  • Africa

Recent Developments of Cell Based Assays Industry

• In December 2021, Thermo Fisher Scientific acquired PPD to enhance its clinical research services for the biopharma and biotech industries
• In March 2020, Danaher acquired General Electric’s Life Sciences Division (and renamed it Cytiva) to enhance its Life Sciences products and services portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst